Oxytocin

Overview

Synthetic oxytocin, sold under the brand name Pitocin among others, is a medication made from the peptide oxytocin. As a medication, it is used to cause contraction of the uterus to start labor, increase the speed of labor, and to stop bleeding following delivery. For this purpose, it is given by injection either into a muscle or into a vein.[1][2] WP

Oxytocin is also available in intranasal spray form for psychiatric, endocrine and weight management use as a supplement. Intranasal oxytocin works on a different pathway than injected oxytocin, primarily along the olfactory nerve crossing the blood–brain barrier to the olfactory lobe in the brain, where dense magnocellular oxytocin neurons receive the nerve impulse quickly. WP

The natural occurrence of oxytocin was discovered in 1906. It is on the World Health Organization's List of Essential Medicines.[3][4][5] WP

Drug class

Oxytocin receptor agonist WP

From the Wikipedia article's infobox.

Uses, dosage and effects

Medical uses

An intravenous infusion of oxytocin is used to induce labor and to support labor in case of slow childbirth if the oxytocin challenge test fails. The physiology of labor stimulated by oxytocin administration is similar to the physiology of spontaneous labor. It is associated with less tachysystole (more than five contractions in 10 minutes, averaged over a 30-minute period, which can but does not always cause fetal distress) than other induction methods and allows achievement of delivery with amniotomy to proceed faster. Whether a high dose is better than a standard dose for labor induction is unclear. It has largely replaced ergometrine as the principal agent to increase uterine tone in acute postpartum hemorrhage. Oxytocin is also used in veterinary medicine to facilitate birth and to stimulate milk release.[6][7][8] WP

The tocolytic agent atosiban (Tractocile) acts as an antagonist of oxytocin receptors. It is registered in many countries for use in suppressing premature labor between 24 and 33 weeks of gestation. It has fewer side effects than drugs previously used for this purpose (such as ritodrine, salbutamol and terbutaline).[9] WP

Oxytocin has not been found to be useful for improving breastfeeding success.[10] WP

Routes of administration

One IU of oxytocin is the equivalent of about 1.68 μg or mcg of pure peptide.[11] WP

• Injection: Clinical doses of oxytocin are given by injection either into a muscle or into a vein to cause contraction of the uterus. Very small amounts (< 1%) do appear to enter the central nervous system in humans when peripherally administered. The compound has a half-life of typically about 3 minutes in the blood when given intravenously. Intravenous administration requires 40 minutes to reach a steady-state concentration and achieve maximum uterine contraction response.[1][12][13] WP⚠ Wikipedia itself has flagged this text: better source needed.
• Buccal: Oxytocin was delivered in buccal tablets, but this is not common practice any more.[14] WP
• Under the tongue: Oxytocin is poorly absorbed sublingually.[15] WP
• Nasal administration: Oxytocin is effectively distributed to the brain when administered intranasally via a nasal spray, after which it reliably crosses the blood–brain barrier and exhibits psychoactive effects in humans. No serious adverse effects with short-term application of oxytocin with 18~40 IU (36–80 mcg) have been recorded. Intranasal oxytocin has a central duration of at least 2.25 hours and as long as 4 hours.[16–20] WP
• Oral: While it was originally assumed that oxytocin administered orally would be destroyed in the gastrointestinal tract, studies have shown that oxytocin is transported by the immunoglobulin RAGE (receptor for advanced glycation end products) across the intestinal epithelium and into the blood. Orally-administered oxytocin has been shown to increase putamen responses to facial emotions in humans. Oxytocin administered orally produces different effects on human behaviour and brain function than when given intranasally, possibly due to variations in the molecular transport and binding mechanisms.[21] WP

Risks and side effects

Contraindications

Oxytocin injection (synthetic) is contraindicated in any of these conditions:[22] WP

• Substantial cephalopelvic disproportion[22] WP
• Unfavorable fetal position or presentation (e.g., transverse lies) undeliverable without conversion before delivery[22] WP
• Obstetric emergencies where maternal or fetal risk-to-benefit ratio favors surgery[22] WP
• Fetal distress when delivery is not imminent[22] WP
• Umbilical cord prolapse[22] WP
• Uterine activity fails to progress adequately[22] WP
• Hyperactive or hypertonic uterus[22] WP
• Vaginal delivery is contraindicated (e.g., invasive cervical carcinoma, active genital herpes infection, total placenta previa, vasa previa, cord presentation or prolapse)[22] WP
• Uterine or cervical scarring from previous cesarean section or major cervical or uterine (e.g., transfundal) surgery[22] WP
• Unengaged fetal head[22] WP
• History of hypersensitivity to oxytocin or any ingredient in the formulation[22] WP

Side effects

Oxytocin is relatively safe when used at recommended doses, and side effects are uncommon. These maternal events have been reported:[23] WP

• Subarachnoid hemorrhage[23] WP
• Increased blood pressure when combined with other medications that raise blood pressure, particularly when used prior to administering epidural anesthesia[24] WP
• Cardiac arrhythmia including increased or decreased heart rate, and premature ventricular contraction[23] WP
• Impaired uterine blood flow or excessive uterine contractions when combined with other medications that cause uterine contraction (carboprost, misoprostol)[24] WP
• Uterine rupture[24] WP
• Afibrinogenemia[23] WP
• Anaphylaxis[1] WP
• Nausea and vomiting[23] WP
• Changes in fetal blood flow[23] WP

Many of these side effects are unable to be differentiated from the risks of normal labor versus oxytocin administration itself.[6][24] WP

Oxytocin during labour is associated with a significantly higher risk of severe postpartum hemorrhage.[25] WP

Excessive dosage or long-term administration (over a period of 24 hours or longer) has been known to result in tetanic uterine contractions, uterine rupture, sometimes fatal. Water intoxication may be exhibited in administration through symptoms such as seizures, comas, neonatal jaundice, and potential fatality. Managed fluid intake and consistent monitoring of sodium levels has been researched as crucial in the safe administration of oxytocin.[26][27] WP

The use of oxytocin during childbirth has been linked to an increased need for other medical interventions, most primarily, through the administration of an epidural anaesthetic. This has been documented as creating a 'cascade effect', potentially causing detrimental impacts to the birthing process. Oxytocin administration also, conversely, decreases the rate of cesarean sections. Use of oxytocin has been found to significantly shorten labor duration. Early oxytocin augmentation has also been found to increase the probability of spontaneous vaginal delivery and reduce the risk of chorioamnionitis or intrauterine infection.[28–33] WP

Since a landmark investigation was published in JAMA Pediatrics by researchers in 2013, the potential link between oxytocin use during childbirth and increased risks of Autism Spectrum Disorder (ASD) in children's development has been a topic of debate. There is no robust evidence in support of oxytocin causing ASD or other neurodevelopmental disorders.[34][35][36] WP

Oxytocin was added to the Institute for Safe Medication Practices's list of High Alert Medications in Acute Care Settings in 2012. The list includes medications that have a high risk for harm if administered incorrectly.[37] WP

During pregnancy, increased uterine motility has led to decreased heart rate, cardiac arrhythmia, seizures, brain damage, and death in the fetus or neonate. Increased uterine motility is a hallmark of both spontaneous labor and induced labor, therefore the risks associated with uterine motility are not specific to this medication.[6][23] WP

Use is linked to an increased risk of postpartum depression in the mother.[38] WP

Certain learning and memory functions are impaired by centrally administered oxytocin. Also, systemic oxytocin administration can impair memory retrieval in certain aversive memory tasks. However, oxytocin does seem to facilitate learning and memory specifically for social information. Healthy males administered intranasal oxytocin show improved memory for human faces, in particular happy faces.[39–42] WP

Pharmacology

Pharmacodynamics

In addition to its oxytocin receptor agonism, oxytocin has been found to act as a positive allosteric modulator (PAM) of the μ- and κ-opioid receptors and this may be involved in its analgesic effects.[43–48] WP

History

History

Oxytocin's uterine-contracting properties were discovered by British pharmacologist Henry Hallett Dale in 1906. Oxytocin's milk ejection property was described by Ott and Scott in 1910 and by Schafer and Mackenzie in 1911.[4][49][50] WP

Oxytocin was the first polypeptide hormone to be sequenced or synthesized. Du Vigneaud was awarded the Nobel Prize in 1955 for his work.[51–54] WP

Etymology

The word oxytocin was coined from the term oxytocic. Greek ὀξύς, oxys, and τόκος, tokos, meaning "quick birth". WP

Legal status

Counterfeits

In African and Asian countries, some oxytocin products were found to be counterfeit medications.[55][56] WP

Chemistry

Formula

C43H66N12O12S2 PC

CAS number

50-56-6 PC

Molar mass (g/mol)

1007.2 PC

IUPAC name (computed by PubChem)

(2S)-1-[(4R,7S,10S,13S,16S,19R)-19-amino-7-(2-amino-2-oxoethyl)-10-(3-amino-3-oxopropyl)-13-[(2S)-butan-2-yl]-16-[(4-hydroxyphenyl)methyl]-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carbonyl]-N-[(2S)-1-[(2-amino-2-oxoethyl)amino]-4-methyl-1-oxopentan-2-yl]pyrrolidine-2-carboxamide PC

SMILES

CC[C@H](C)[C@H]1C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@H](C(=O)N1)CC2=CC=C(C=C2)O)N)C(=O)N3CCC[C@H]3C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N)CC(=O)N)CCC(=O)N PC

InChIKey

XNOPRXBHLZRZKH-DSZYJQQASA-N PC

PubChem CID

439302

Harm reduction information

No harm reduction data is on file for this compound yet. That means no dose, timing or combination data from PsychonautWiki or TripSit. Please don't guess a dose from similar compounds. If you have taken it and feel unwell, contact emergency services or a poison control center.

User reports

Pop culture

No references added yet.

Sources

1. Other Oxytocin
2. Other The Oxford Handbook of Prosocial Behavior. 2015
3. Other Hurlemann R, Grinevich V. Behavioral Pharmacology of Neuropeptides: Oxytocin. 2018
4. Journal / agency Dale HH. On some physiological actions of ergot. The Journal of Physiology. May 1906. doi:10.1113/jphysiol.1906.sp001148 · PMID 16992821 · PMC1465771
5. Other Organization WH. The selection and use of essential medicines 2023: web annex A: World Health Organization model list of essential medicines: 23rd list (2023). 2023
6. Other Induction of Labor
7. Journal / agency Pennington E, Bell S, Hill JE. Should video laryngoscopy or direct laryngoscopy be used for adults undergoing endotracheal intubation in the pre-hospital setting? A critical appraisal of a systematic review. Cochrane Database of Systematic Reviews. 2023. doi:10.1002/14651858 · PMID 38812899 · PMC7616025
8. Journal / agency Hofmeyr GJ, Gülmezoglu AM, Pileggi C. Vaginal misoprostol for cervical ripening and induction of labour. The Cochrane Database of Systematic Reviews. October 2010. doi:10.1002/14651858.CD000941.pub2 · PMID 20927722 · PMC7061246
9. Journal / agency Budden A, Chen LJ, Henry A. High-dose versus low-dose oxytocin infusion regimens for induction of labour at term. The Cochrane Database of Systematic Reviews. 9 October 2014. doi:10.1002/14651858.CD009701.pub2 · PMID 25300173 · PMC8932234
10. Other Oxytocin use while Breastfeeding
11. Other WHO International Standard OXYTOCIN 4th International Standard NIBSC code: 76/575 Instructions for use (Version 4.0, Dated 30/04/2013)
12. Journal / agency Baribeau DA, Anagnostou E. Oxytocin and vasopressin: linking pituitary neuropeptides and their receptors to social neurocircuits. Frontiers in Neuroscience. 2015. doi:10.3389/fnins.2015.00335 · PMID 26441508 · PMC4585313
13. Journal / agency Seitchik J, Castillo M. Oxytocin augmentation of dysfunctional labor. I. Clinical data. American Journal of Obstetrics and Gynecology. December 1982. doi:10.1097/00006254-198307000-00010 · PMID 7148921
14. Journal / agency Mehta AC. Buccal and oral drugs: induction of labour. Acta Chirurgica Hungarica. 1986. PMID 3469841
15. Journal / agency De Groot AN, Vree TB, Hekster YA, Pesman GJ, Sweep FC, Van Dongen PJ, Van Roosmalen J. Bioavailability and pharmacokinetics of sublingual oxytocin in male volunteers. The Journal of Pharmacy and Pharmacology. 1995. doi:10.1111/j.2042-7158.1995.tb06716.x · PMID 8568623
16. Other Malenka RC, Nestler EJ, Hyman SE. Molecular Neuropharmacology: A Foundation for Clinical Neuroscience. 2009
17. Journal / agency McGregor IS, Callaghan PD, Hunt GE. From ultrasocial to antisocial: a role for oxytocin in the acute reinforcing effects and long-term adverse consequences of drug use?. British Journal of Pharmacology. May 2008. doi:10.1038/bjp.2008.132 · PMID 18475254 · PMC2442436
18. Journal / agency Lee SY, Lee AR, Hwangbo R, Han J, Hong M, Bahn GH. Is Oxytocin Application for Autism Spectrum Disorder Evidence-Based?. Experimental Neurobiology. 2015. doi:10.5607/en.2015.24.4.312 · PMID 26713079 · PMC4688331
19. Journal / agency Weisman O, Zagoory-Sharon O, Feldman R. Intranasal oxytocin administration is reflected in human saliva. Psychoneuroendocrinology. September 2012. doi:10.1016/j.psyneuen.2012.02.014 · PMID 22436536
20. Journal / agency Huffmeijer R, Alink LR, Tops M, Grewen KM, Light KC, Bakermans-Kranenburg MJ, Ijzendoorn MH. Salivary levels of oxytocin remain elevated for more than two hours after intranasal oxytocin administration. Neuro Endocrinology Letters. 2012. PMID 22467107
21. Journal / agency Kou J, Lan C, Zhang Y, Wang Q, Zhou F, Zhao Z, Montag C, Yao S, Becker B, Kendrick KM. In the nose or on the tongue? Contrasting motivational effects of oral and intranasal oxytocin on arousal and reward during social processing. Translational Psychiatry. February 2021. doi:10.1038/s41398-021-01241-w · PMID 33542175 · PMC7862637
22. Other Oxytocin - FDA prescribing information, side effects and uses
23. Other Pitocin (drug label for professionals)
24. Journal / agency Osilla EV, Patel P, Sharma S. StatPearls [Internet]. 2025-02-15. PMID 29939625
25. Journal / agency Belghiti J, Kayem G, Dupont C, Rudigoz RC, Bouvier-Colle MH, Deneux-Tharaux C. Oxytocin during labour and risk of severe postpartum haemorrhage: a population-based, cohort-nested case-control study. BMJ Open. 2011. doi:10.1136/bmjopen-2011-000514 · PMID 22189353 · PMC3334825
26. Journal / agency D'Souza SW, Lieberman B, Cadman J, Richards B. Oxytocin induction of labour: hyponatraemia and neonatal jaundice. European Journal of Obstetrics, Gynecology, and Reproductive Biology. September 1986. doi:10.1016/0028-2243(86)90119-x · PMID 3770280
27. Journal / agency Emre U, Kadıoğlu G, Ünal A, Atasoy HT. Case report: hyponatremia and generalized convulsion after intravenous oxytocin infusion. Journal of the Turkish-German Gynecological Association. March 2009
28. Journal / agency Hidalgo-Lopezosa P, Hidalgo-Maestre M, Rodríguez-Borrego MA. Labor stimulation with oxytocin: effects on obstetrical and neonatal outcomes. Revista Latino-Americana de Enfermagem. 2016. doi:10.1590/1518-8345.0765.2744 · PMID 27463109 · PMC4982443
29. Journal / agency Lothian JA. Healthy birth practice #4: avoid interventions unless they are medically necessary. The Journal of Perinatal Education. 2014. doi:10.1891/1058-1243.23.4.198 · PMID 25411540 · PMC4235054
30. Journal / agency Hitzeman N, Chin S. Epidural analgesia for labor pain. American Family Physician. August 2012. PMID 22962986
31. Journal / agency Wei S, Wo BL, Qi HP, Xu H, Luo ZC, Roy C, Fraser WD. Early amniotomy and early oxytocin for prevention of, or therapy for, delay in first stage spontaneous labour compared with routine care. The Cochrane Database of Systematic Reviews. August 2013. doi:10.1002/14651858.CD006794.pub4 · PMID 23926074 · PMC11528244
32. Journal / agency Wei SQ, Luo ZC, Xu H, Fraser WD. The effect of early oxytocin augmentation in labor: a meta-analysis. Obstetrics and Gynecology. September 2009. doi:10.1097/AOG.0b013e3181b11cb8 · PMID 19701046
33. Journal / agency Son M, Roy A, Stetson BT, Grady NT, Vanecko MC, Bond N, Swanson K, Grobman WA, Miller ES, Peaceman AM. High-Dose Compared With Standard-Dose Oxytocin Regimens to Augment Labor in Nulliparous Women: A Randomized Controlled Trial. Obstetrics and Gynecology. June 2021. doi:10.1097/AOG.0000000000004399 · PMID 33957657
34. Journal / agency Gregory SG, Anthopolos R, Osgood CE, Grotegut CA, Miranda ML. Association of autism with induced or augmented childbirth in North Carolina Birth Record (1990-1998) and Education Research (1997-2007) databases. JAMA Pediatrics. October 2013. doi:10.1001/jamapediatrics.2013.2904 · PMID 23938610
35. Journal / agency Oberg AS, D'Onofrio BM, Rickert ME, Hernandez-Diaz S, Ecker JL, Almqvist C, Larsson H, Lichtenstein P, Bateman BT. Association of Labor Induction With Offspring Risk of Autism Spectrum Disorders. JAMA Pediatrics. September 2016. doi:10.1001/jamapediatrics.2016.0965 · PMID 27454803 · PMC5297393
36. Journal / agency Lønfeldt NN, Verhulst FC, Strandberg-Larsen K, Plessen KJ, Lebowitz ER. Assessing risk of neurodevelopmental disorders after birth with oxytocin: a systematic review and meta-analysis. Psychological Medicine. April 2019. doi:10.1017/S0033291718003021 · PMID 30444210
37. Other High-Alert Medications in Acute Care Settings. 16 November 2017
38. Journal / agency Kroll-Desrosiers AR, Nephew BC, Babb JA, Guilarte-Walker Y, Moore Simas TA, Deligiannidis KM. Association of peripartum synthetic oxytocin administration and depressive and anxiety disorders within the first postpartum year. Depression and Anxiety. February 2017. doi:10.1002/da.22599 · PMID 28133901 · PMC5310833
39. Journal / agency Gimpl G, Fahrenholz F. The oxytocin receptor system: structure, function, and regulation. Physiological Reviews. April 2001. doi:10.1152/physrev.2001.81.2.629 · PMID 11274341
40. Journal / agency de Oliveira LF, Camboim C, Diehl F, Consiglio AR, Quillfeldt JA. Glucocorticoid-mediated effects of systemic oxytocin upon memory retrieval. Neurobiology of Learning and Memory. January 2007. doi:10.1016/j.nlm.2006.05.006 · PMID 16997585
41. Journal / agency Guastella AJ, Mitchell PB, Mathews F. Oxytocin enhances the encoding of positive social memories in humans. Biological Psychiatry. August 2008. doi:10.1016/j.biopsych.2008.02.008 · PMID 18343353
42. Journal / agency Rimmele U, Hediger K, Heinrichs M, Klaver P. Oxytocin makes a face in memory familiar. The Journal of Neuroscience. January 2009. doi:10.1523/JNEUROSCI.4260-08.2009 · PMID 19129382 · PMC6664913
43. Journal / agency Drakopoulos A, Moianos D, Prifti GM, Zoidis G, Decker M. Opioid Ligands Addressing Unconventional Binding Sites and More Than One Opioid Receptor Subtype. ChemMedChem. July 2022. doi:10.1002/cmdc.202200169 · PMID 35560796
44. Journal / agency Kaczyńska K, Wojciechowski P. Non-Opioid Peptides Targeting Opioid Effects. Int J Mol Sci. December 2021. doi:10.3390/ijms222413619 · PMID 34948415 · PMC8709238
45. Journal / agency Carter CS, Kingsbury MA. Oxytocin and oxygen: the evolution of a solution to the 'stress of life'. Philos Trans R Soc Lond B Biol Sci. August 2022. doi:10.1098/rstb.2021.0054 · PMID 35856299 · PMC9272143
46. Journal / agency Meguro Y, Miyano K, Hirayama S, Yoshida Y, Ishibashi N, Ogino T, Fujii Y, Manabe S, Eto M, Nonaka M, Fujii H, Ueta Y, Narita M, Sata N, Yada T, Uezono Y. Neuropeptide oxytocin enhances μ opioid receptor signaling as a positive allosteric modulator. J Pharmacol Sci. May 2018. doi:10.1016/j.jphs.2018.04.002 · PMID 29716811
47. Journal / agency Miyano K, Yoshida Y, Hirayama S, Takahashi H, Ono H, Meguro Y, Manabe S, Komatsu A, Nonaka M, Mizuguchi T, Fujii H, Higami Y, Narita M, Uezono Y. Oxytocin Is a Positive Allosteric Modulator of κ-Opioid Receptors but Not δ-Opioid Receptors in the G Protein Signaling Pathway. Cells. October 2021. doi:10.3390/cells10102651 · PMID 34685631 · PMC8534029
48. Journal / agency Mizuguchi T, Miyano K, Yamauchi R, Yoshida Y, Takahashi H, Yamazaki A, Ono H, Inagaki M, Nonaka M, Uezono Y, Fujii H. The first structure-activity relationship study of oxytocin as a positive allosteric modulator for the µ opioid receptor. Peptides. January 2023. doi:10.1016/j.peptides.2022.170901 · PMID 36347314
49. Journal / agency Ott I, Scott JC. The Action of Infundibulum upon Mammary Secretion. Proceedings of the Society for Experimental Biology and Medicine. 1910. doi:10.3181/00379727-8-27
50. Journal / agency Schafer EA, Mackenzie K. The Action of Animal Extracts on Milk Secretion. Proceedings of the Royal Society B. July 1911. doi:10.1098/rspb.1911.0042
51. Journal / agency Du Vigneaud V, Ressler C, Trippett S. The sequence of amino acids in oxytocin, with a proposal for the structure of oxytocin. The Journal of Biological Chemistry. December 1953. doi:10.1016/S0021-9258(18)49238-1 · PMID 13129273
52. Journal / agency du Vigneaud V, Ressler C, Swan JM, Roberts CW, Katsoyannis PG, Gordon S. The synthesis of an octapeptide amide with the hormonal activity of oxytocin. J. Am. Chem. Soc. 1953. doi:10.1021/ja01115a553
53. Journal / agency du Vigneaud V, Ressler C, Swan JM, Roberts CW, Katsoyannis PG. The synthesis of oxytocin. J. Am. Chem. Soc. June 1954. doi:10.1021/ja01641a004
54. Journal / agency Du Vigneaud V. Trail of sulfur research: from insulin to oxytocin. Science. June 1956. doi:10.1126/science.123.3205.967 · PMID 13324123
55. Journal / agency Torloni MR, Gomes Freitas C, Kartoglu UH, Metin Gülmezoglu A, Widmer M. Quality of oxytocin available in low- and middle-income countries: a systematic review of the literature. BJOG: An International Journal of Obstetrics and Gynaecology. December 2016. doi:10.1111/1471-0528.13998 · PMID 27006180
56. Journal / agency Stanton C, Koski A, Cofie P, Mirzabagi E, Grady BL, Brooke S. Uterotonic drug quality: an assessment of the potency of injectable uterotonic drugs purchased by simulated clients in three districts in Ghana. BMJ Open. 2012. doi:10.1136/bmjopen-2011-000431 · PMID 22556159 · PMC3346944

Text and values on this page are quoted from Wikipedia (CC BY-SA 4.0), PubChem (public domain). Each value links to the exact revision it came from.